Titlebook: Cardio-Oncology; Management of Toxici Antonio Russo,Nicola Maurea,Antonio Giordano Book 2022 The Editor(s) (if applicable) and The Author(s

Harass

,Grundlegende notfallmedizinische Ma?nahmen,y recognized risk factors combined with immunotherapy may increase the risk of cardiac injury. Therefore, it is important to assess a patient’s overall cardiovascular risk and treat any underlying cardiovascular conditions before commencing immunotherapy.

Solace

Background: Immunology and Cancer,Several different therapeutic approaches have consistently reported durable responses, showing that cancer immunotherapy is a promising and active treatment modality. Immune-related approaches have been associated with manageable safety profiles that are different from traditional therapies. In this

親愛

defeatist

GLOOM

Cardiac Risk Factors for Immunotherapy,atment, alone or in combination. The most common cardiac manifestation is myocarditis followed by pericardial diseases, conduction disorders, and arrhythmias. Although we lack the means to identify patients at high or low risk of immunotherapy-induced cardiotoxicity, it is feasible that the currentl

muscle-fibers

Biomarkers of Early Cardiotoxicity,er drugs are available, the validation of these markers is still challenging, above all when applied to the early identification of severe cardiac side effects. Some biomarkers have been tested for this purpose, but only troponins and natriuretic peptides seem to play a role in clinical routine sett

Inkling

Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist,scular complications. Immunotherapy is associated with a spectrum of side effects termed “immune-related adverse events” that include dermatologic, gastrointestinal, hepatic, and endocrine events. Temporary immunosuppression with glucocorticoids, tumor necrosis factor alpha antagonists, and mycophen

合唱團(tuán)

landmark

9樓

半身雕像

9樓